Scilex Holding Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCLX research report →
Price Chart
About the company
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1. 8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles.
- CEO
- Henry H. Ji
- IPO
- 2021
- Employees
- 34
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on SCLX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.98M
- P/E
- -0.01
- Fwd P/E
- 1.24
- PEG
- 0.00
- P/S
- 0.13
- P/B
- -0.01
- EV/EBITDA
- -0.27
- Div Yield
- 0.00%
- Gross Margin
- 41.49%
- Op Margin
- -903.52%
- Net Margin
- -1414.57%
- ROE
- 189.81%
- ROIC
- 162.60%
Latest fiscal year · YoY change
- Revenue
- $30.25M-46.5%
- Gross Profit
- $15.03M-62.3%
- Op Income
- $-272,304,000
- Net Income
- $-358,734,000-392.7%
- EPS
- $-36.48-87.8%
- OCF Growth
- -80.3%
- FCF Growth
- -80.4%
- 52W High
- $23.03
- 52W Low
- $0.50
- 50D MA
- $2.95
- 200D MA
- $4.96
- Beta
- 1.93
- RSI (14)
- 8
- Avg Volume
- 56.11K
No earnings-call transcripts are available for SCLX yet.
- Free Float
- 88.3%
- Shares Outstanding
- 7.03M
- Float Shares
- 6.21M
of shares held by institutions
72 13F filers
Buy/sell ratio 1.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 301.29K | 0 |
| Vanguard Group Inc | 295.02K | ▲ 12.60K |
| Jacobs Levy Equity Management, Inc | 113.19K | ▲ 72.03K |
| Blackrock, Inc. | 94.67K | ▼ 14.74K |
| Vanguard Fiduciary Trust Co | 45.82K | 0 |
| State Street Corp | 35.03K | ▼ 344 |
| Marshall Wace, Llp | 33.80K | ▲ 33.80K |
| Ubs Group AG | 31.41K | ▼ 1.97K |
| Renaissance Technologies LLC | 31.36K | ▼ 1.70K |
| Ashton Thomas Private Wealth, LLC | 23.83K | ▲ 5.35K |
| Hrt Financial LP | 22.47K | ▲ 22.47K |
| Price T Rowe Associates Inc | 20.92K | 0 |
Held by 34 ETFs
Biggest fund positions in SCLX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 3, 26 | SCLX Stock Acquisition JV LLC | other | 500,000 |
| Apr 17, 26 | Ma Stephen Hoi | buy | 650,000 |
| Apr 16, 26 | Ji Henry | buy | 3,250,000 |
| Apr 17, 26 | Ji Henry | sell | 650,000 |
| Dec 26, 25 | Scilex Holding Co | sell | 3,689,016 |
| Dec 29, 25 | Scilex Holding Co | sell | 7,310,984 |
| Dec 30, 25 | Scilex Holding Co | sell | 9,657,300 |
| Oct 8, 25 | Wu Yue Alexander | other | 20,000 |
| Oct 8, 25 | Ma Stephen Hoi | other | 60,000 |
| Oct 8, 25 | Chun Jay | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SCLX coverage
Recent articles, reports, and earnings notes.
No research on SCLX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SCLX report →Datavault AI Stock Crashes — Financials Cannot Be Trusted: What You Need to Know
benzinga.com · Oct 27
Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)
defenseworld.net · Oct 11
Iterum Therapeutics (NASDAQ:ITRM) vs. Scilex (NASDAQ:SCLX) Critical Review
defenseworld.net · Sep 28
Head to Head Survey: Scilex (NASDAQ:SCLX) versus Incannex Healthcare (NASDAQ:IXHL)
defenseworld.net · Sep 26
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
globenewswire.com · Jul 7
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
globenewswire.com · Jul 6
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
globenewswire.com · Jul 6
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
gurufocus.com · Jun 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.